Бевацизумаб: Қолданылуы мен тиімділігінің талдауы

Medication

Bevacizumab has also been examined as an add on to other chemotherapy drugs in people with non metastatic colon cancer. The data from two large randomized studies showed no benefit in preventing the cancer from returning and a potential to cause harm in this setting. In the EU, bevacizumab in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adults with metastatic carcinoma of the colon or rectum. The National Comprehensive Cancer Network recommends bevacizumab as standard first line treatment in combination with any platinum based chemotherapy, followed by maintenance bevacizumab until disease progression. Higher doses are usually given with carboplatin based chemotherapy, whereas the lower dose is usually given with cisplatin based chemotherapy. In the EU, bevacizumab, in addition to platinum based chemotherapy, is indicated for first line treatment of adults with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. The combined data from four different clinical trials showed that bevacizumab neither prolonged overall survival nor slowed disease progression sufficiently to outweigh the risk it presents to patients. This only prevented Genentech from marketing bevacizumab for breast cancer. Doctors are free to prescribe bevacizumab off label, although insurance companies are less likely to approve off label treatments. In June 2011, an FDA panel unanimously rejected an appeal by Roche. A panel of cancer experts ruled for a second time that Avastin should no longer be used in breast cancer patients, clearing the way for the US government to remove its endorsement from the drug. The June 2011 meeting of the FDA's oncologic drug advisory committee was the last step in an appeal by the drug's maker. The committee concluded that breast cancer clinical studies of patients taking Avastin have shown no advantage in survival rates, no improvement in quality of life, and significant side effects. On 11 October 2011, the FDA announced that the agency was revoking the agency's approval of the breast cancer indication for bevacizumab after concluding that the drug had not been shown to be safe and effective for that use. In the EU, bevacizumab in combination with paclitaxel is indicated for first line treatment of adults with metastatic breast cancer. following earlier reports of activity EU approval was granted in 2007. In the EU, bevacizumab in combination with interferon alfa 2a is indicated for first line treatment of adults with advanced and/or metastatic renal cell cancer. The FDA granted accelerated approval for the treatment of recurrent glioblastoma multiforme in May 2009. A 2018 Cochrane review deemed there to not be good evidence for its use in recurrences either. Many retina specialists have noted impressive results in the setting of CNV, proliferative diabetic retinopathy, neovascular glaucoma, diabetic macular edema, retinopathy of prematurity and macular edema secondary to retinal vein occlusions. Several reviews concluded that similar results concerning effects and safety were obtained using either bevacizumab or ranibizumab. The latter is an antibody fragment specifically designed and approved for the treatment of eye disease. Today there is no doubt that patients injected with bevacizumab intravitrealy died as a consequence of the treatment. The risk to die is particularly high when the patients had a cardiovascular 29429131 or cerebrovascular. event before intravitreal bevacizumab treatment. In the years between 2006 and 2014 groups with higher and lower risk for thrombotic angiopathy were not defined before intravitreal injections of bevacizumab but was recommended later. Progression free survival was increased to 18 months from 13 months.

In the EU, bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in people who cannot receive platinum therapy, is indicated for the treatment of adults with persistent, recurrent, or metastatic carcinoma of the cervix. Bevacizumab is used off label to treat neovascular AMD.

Bevacizumab inhibits the growth of blood vessels, which is part of the body's normal healing and maintenance. The body grows new blood vessels in wound healing, and as collateral circulation around blocked or atherosclerotic blood vessels. One concern is that bevacizumab will interfere with these normal processes, and worsen conditions like coronary artery disease or peripheral artery disease. The main side effects are hypertension and heightened risk of bleeding. Bowel perforation has been reported. Fatigue and infection are also common. In advanced lung cancer, less than half of patients qualify for treatment. Nasal septum perforation and renal thrombotic microangiopathy have been reported. In December 2010, the FDA warned of the risk of developing perforations in the body, including in the nose, stomach, and intestines. In 2013, Hoffmann La Roche announced that the drug was associated with 52 cases of necrotizing fasciitis from 1997 to 2012, of which 17 patients died. About 2/3 of cases involved patients with colorectal cancer, or patients with gastrointestinal perforations or fistulas. These effects are largely avoided in ophthalmological use since the drug is introduced directly into the eye thus minimizing any effects on the rest of the body. Neurological adverse events include reversible posterior encephalopathy syndrome. Ischemic and hemorrhagic strokes are also possible. Protein in the urine occurs in approximately 20% of people. This does not require permanent discontinuation of the drug. Nonetheless, the presence of nephrotic syndrome necessitates permanent discontinuation of bevacizumab. VEGF A is a growth factor protein that stimulates angiogenesis in a variety of diseases, especially in cancer. By binding VEGF A, bevacizumab should act outside the cell, but in some cases (cervical and breast cancer) it is taken up by cells through constitutive endocytosis. It also is taken up by retinal photoreceptor cells after intravitreal injection.

Bevacizumab was originally derived from a mouse monoclonal antibody generated from mice immunized with the 165 residue form of recombinant human vascular endothelial growth factor. It was humanized by retaining the binding region and replacing the rest with a human full light chain and a human truncated IgG1 heavy chain, with some other substitutions. The resulting plasmid was transfected into Chinese hamster ovary cells which are grown in industrial fermentation systems.

Bevacizumab is a recombinant humanized monoclonal antibody and in 2004, it became the first clinically used angiogenesis inhibitor. Its development was based on the discovery of human vascular endothelial growth factor (VEGF), a protein that stimulated blood vessel growth, in the laboratory of Genentech scientist Napoleone Ferrara. Ferrara later demonstrated that antibodies against VEGF inhibit tumor growth in mice. His work validated the hypothesis of Judah Folkman, proposed in 1971, that stopping angiogenesis might be useful in controlling cancer growth. It has since been approved for use in certain lung cancers, renal cancers, ovarian cancers, and glioblastoma multiforme of the brain. In 2008, bevacizumab was approved for breast cancer by the FDA, but the approval was revoked on 18 November 2011 because, although there was evidence that it slowed progression of metastatic breast cancer, there was no evidence that it extended life or improved quality of life, and it caused adverse effects including severe high blood pressure and hemorrhaging. In 2008, the FDA gave bevacizumab provisional approval for metastatic breast cancer, subject to further studies. The FDA's advisory panel had recommended against approval. In July 2010, after new studies failed to show a significant benefit, the FDA's advisory panel recommended against the indication for advanced breast cancer. Genentech requested a hearing, which was granted in June 2011. The FDA ruled to withdraw the breast cancer indication in November 2011. FDA approval is required for Genentech to market a drug for that indication. Doctors may sometimes prescribe it for that indication, although insurance companies are less likely to pay for it. It has been funded by the English NHS Cancer Drugs Fund, but in January 2015 it was proposed to remove it from the approved list. It remains on the Cancer Drugs Fund as of March 2023.

In 2015, there was a fierce debate in the UK and other European countries concerning the choice of prescribing bevacizumab or ranibizumab (Lucentis) for wet AMD. In the UK, part of the tension was between on the one hand, both the European Medicines Agency and the Medicines and Healthcare products Regulatory Agency which had approved Lucentis but not Avastin for wet AMD, and their interest in ensuring that doctors do not use medicines off label when there are other, approved medications for the same indication, and on the other hand, NICE in the UK, which sets treatment guidelines, and has been unable so far to appraise Avastin as a first line treatment, in order to save money for the National Health Service.

In March 2007, the European Commission approved bevacizumab in combination with paclitaxel for the first line treatment of metastatic breast cancer. In 2008, the FDA approved bevacizumab for use in breast cancer. A panel of outside advisers voted 5 to 4 against approval, but their recommendations were overruled. The panel expressed concern that data from the clinical trial did not show any increase in quality of life or prolonging of life for patients—two important benchmarks for late stage cancer treatments. The clinical trial did show that bevacizumab reduced tumor volumes and showed an increase in progression free survival time. It was based on this data that the FDA chose to overrule the recommendation of the panel of advisers. This decision was lauded by patient advocacy groups and some oncologists. Other oncologists felt that granting approval for late stage cancer therapies that did not prolong or increase the quality of life for patients would give license to pharmaceutical companies to ignore these important benchmarks when developing new late stage cancer therapies. The investigation is ongoing, but differences in the outer packaging make identification of the bogus drugs simple for medical providers. Roche analyzed three bogus vials of Avastin and found they contained salt, starch, citrate, isopropanol, propanediol, t butanol, benzoic acid, di fluorinated benzene ring, acetone and phthalate moiety, but no active ingredients of the cancer drug. According to Roche, the levels of the chemicals were not consistent; whether the chemicals were at harmful concentrations could not therefore be determined. The counterfeit Avastin has been traced back to Egypt, and it entered legitimate supply chains via Europe to the United States.

In July 2014, two pharming companies, PlantForm and PharmaPraxis, announced plans to commercialize a biosimilar version of bevacizumab made using a tobacco expression system in collaboration with the Fraunhofer Center for Molecular Biology. In September 2017, the US FDA approved Amgen's biosimilar (generic name bevacizumab awwb, product name Mvasi) for six cancer indications. In January 2018, Mvasi was approved for use in the European Union. In February 2019, Zirabev was approved for use in the European Union. Zirabev was approved for medical use in the United States in June 2019, and in Australia in November 2019. In September 2020, Equidacent was approved for use in the European Union. In January 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Alymsys, intended for the treatment of carcinoma of the colon or rectum, breast cancer, non small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix. In January 2021, Onbevzi was approved for medical use in the European Union. In June 2019, and June 2021, Zirabev was approved for medical use in Canada. Oyavas was approved for medical use in the European Union in March 2021. Abevmy was approved for medical use in the European Union in April 2021, and in Australia in September 2021. In September 2021, Bambevi was approved for medical use in Canada. Bevacip and Bevaciptin were approved for medical use in Australia in November 2021. In November 2021, Abevmy and Aybintio were approved for medical use in Canada. In April 2022, bevacizumab maly (Alymsys) was approved for medical use in the United States. In September 2022, bevacizumab adcd (Vegzelma) was approved for medical use in the United States. In June 2023, Enzene Biosciences launched its bevacizumab biosimilar in India. Bevacizumab tnjn (Avzivi) was approved for medical use in the United States in December 2023.

A study released in April 2009, found that bevacizumab is not effective at preventing recurrences of non metastatic colon cancer following surgery. Bevacizumab has been tested in ovarian cancer where it has shown improvement in progression free survival but not in overall survival. and glioblastoma multiforme where it failed to improve overall survival. Bevacizumab has been investigated as a possible treatment of pancreatic cancer, as an addition to chemotherapy, but studies have shown no improvement in survival. It may also cause higher rates of high blood pressure, bleeding in the stomach and intestine, and intestinal perforations. The drug has also undergone trials as an addition to established chemotherapy protocols and surgery in the treatment of pediatric osteosarcoma, and other sarcomas, such as leiomyosarcoma. Bevacizumab has been studied as a treatment for cancers that grow from the nerve connecting the ear and the brain.